Simplex Trading’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13.1K Sell
4,866
-11,570
-70% -$21.4K ﹤0.01% 7465
2026
Q1
$19.7K Buy
16,436
+14,807
+909% +$18K ﹤0.01% 6794
2025
Q4
$1.6K Buy
+1,629
New +$1.96K ﹤0.01% 7902
2025
Q3
Sell
-38,019
Closed -$41K 9329
2025
Q2
$42K Buy
38,019
+23,639
+164% +$27.5K ﹤0.01% 6095
2025
Q1
$11K Buy
+14,380
New +$17.6K ﹤0.01% 7024
2024
Q4
Sell
-178
Closed -$449 8823
2024
Q3
$0 Sell
178
-1,304
-88% -$5.07K ﹤0.01% 8795
2024
Q2
$4K Sell
1,482
-138
-9% -$604 ﹤0.01% 7977
2024
Q1
$11K Buy
1,620
+171
+12% +$1.06K ﹤0.01% 7537
2023
Q4
$5K Buy
1,449
+1,130
+354% +$2.67K ﹤0.01% 7846
2023
Q3
$0 Sell
319
-9,122
-97% -$30.2K ﹤0.01% 8978
2023
Q2
$44K Sell
9,441
-895
-9% -$4.94K ﹤0.01% 5962
2023
Q1
$58K Buy
10,336
+8,832
+587% +$53.3K ﹤0.01% 5756
2022
Q4
$15K Buy
1,504
+139
+10% +$2.61K ﹤0.01% 7136
2022
Q3
$30K Buy
1,365
+1,192
+689% +$34.4K ﹤0.01% 7072
2022
Q2
$4K Sell
173
-10,244
-98% -$283K ﹤0.01% 8954
2022
Q1
$403K Buy
10,417
+9,991
+2,345% +$387K ﹤0.01% 4128
2021
Q4
$24K Buy
+426
New +$24.1K ﹤0.01% 8147
2020
Q4
Sell
-19,284
Closed -$1.2M 8542
2020
Q3
$770K Buy
+19,284
New +$673K ﹤0.01% 2534
2020
Q1
Sell
-1,579
Closed -$39.9K 7764
2019
Q4
$30K Sell
1,579
-8,809
-85% -$140K ﹤0.01% 5650
2019
Q3
$161K Sell
10,388
-342
-3% -$6.56K ﹤0.01% 3793
2019
Q2
$217K Sell
10,730
-7,683
-42% -$138K ﹤0.01% 3385
2019
Q1
$323K Buy
18,413
+10,019
+119% +$158K ﹤0.01% 3114
2018
Q4
$107K Buy
8,394
+8,280
+7,263% +$115K ﹤0.01% 3801
2018
Q3
$1K Sell
114
-13,051
-99% -$154K ﹤0.01% 7181
2018
Q2
$149K Sell
13,165
-16,297
-55% -$180K ﹤0.01% 3820
2018
Q1
$287K Buy
29,462
+25,468
+638% +$244K 0.01% 1009
2017
Q4
$24K Buy
3,994
+3,890
+3,740% +$17.4K ﹤0.01% 3125
2017
Q3
$0 Buy
+104
New +$354 ﹤0.01% 6082

Other funds holding FATE

Simplex Trading's FATE Position: Q2 2026 in Review

Simplex Trading reduced its Fate Therapeutics (FATE) stake by 70% in Q2 2026, selling an estimated $21.4K and leaving 4,866 shares worth $13.1K. The position accounts for ﹤0.01% of the portfolio, ranked #7465.

Simplex Trading first reported a position in FATE in Q3 2017 and has held it in 28 quarters since. The position peaked at $770K in Q3 2020. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Simplex Trading held 4,866 shares of Fate Therapeutics worth $13.1K as of Q2 2026.
  • Simplex Trading sold 11,570 Fate Therapeutics shares in Q2 2026, an estimated $21.4K.
  • Fate Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #7465 holding.
  • Simplex Trading first reported a position in Fate Therapeutics in Q3 2017 and has held it in 28 quarters since.
  • Simplex Trading's Fate Therapeutics position peaked at $770K in Q3 2020.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.